Mark A. Goldsmith - 01 Sep 2023 Form 4 Insider Report for Revolution Medicines, Inc. (RVMD)

Role
President and Chief Executive Officer, Director
Signature
/s/ Jack Anders, as attorney-in fact for Mark A. Goldsmith
Issuer symbol
RVMD
Transactions as of
01 Sep 2023
Net transactions value
-$1,378,809
Form type
4
Filing time
06 Sep 2023, 20:05:26 UTC
Previous filing
03 Mar 2023
Next filing
20 Sep 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RVMD Common Stock Options Exercise $9,716 +17,993 +5% $0.5400* 375,379 01 Sep 2023 Direct F1, F2, F3
transaction RVMD Common Stock Options Exercise $13,448 +12,007 +3.2% $1.12* 387,386 01 Sep 2023 Direct F1, F2, F3
transaction RVMD Common Stock Sale $1,051,563 -30,000 -7.7% $35.05 357,386 01 Sep 2023 Direct F1, F2, F3, F4
transaction RVMD Common Stock Sale $175,191 -5,000 -12% $35.04 35,424 01 Sep 2023 Trust F5, F6, F7
transaction RVMD Common Stock Sale $175,219 -5,000 -12% $35.04 35,424 01 Sep 2023 Trust F8, F9, F10
holding RVMD Common Stock 327,547 01 Sep 2023 Trust F11

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction RVMD Stock Option (Right to Buy) Options Exercise $0 -17,993 -8.1% $0.000000 205,503 01 Sep 2023 Common Stock 17,993 $0.5400 Direct F1
transaction RVMD Stock Option (Right to Buy) Options Exercise $0 -12,007 -21% $0.000000 46,479 01 Sep 2023 Common Stock 12,007 $1.12 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Transaction made pursuant to a 10b5-1 trading plan adopted by Mark A. Goldsmith on November 22, 2022.
F2 Includes 190,000 restricted stock units.
F3 Includes 1,514 shares acquired under the Issuer's Employee Stock Purchase Plan on May 31, 2023.
F4 This transaction was executed in multiple trades at prices ranging from $35.00 to $35.24. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F5 Transaction made pursuant to a 10b5-1 trading plan adopted by the Jonathan Henry Goldsmith Trust on November 21, 2022.
F6 This transaction was executed in multiple trades at prices ranging from $35.00 to $35.16. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F7 Held by Jonathan Henry Goldsmith Trust under the Goldsmith Children's 2011 Irrevocable Education Trust, dated December 15, 2011.
F8 Transaction made pursuant to a 10b5-1 trading plan adopted by the Rebecca Eve Goldsmith Trust on November 21, 2022.
F9 This transaction was executed in multiple trades at prices ranging from $35.00 to $35.22. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F10 Held by Rebecca Eve Goldsmith Trust under the Goldsmith Children's 2011 Irrevocable Education Trust, dated December 15, 2011.
F11 Held by Mark A. Goldsmith and Anne E. Midler 2002 Revocable Living Trust.

Remarks:

President and Chief Executive Officer